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where x and y are integers from 3 to 16, Z- is an anion 
such as a halogen and n is an integer from 50 to 150 are 
found to bind negatively charged mammalian cells such 
as malignant cells and can be utilized to selectively 
inhibit the growth of malignant cells in vitro. 
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exhibit any specificity for tumor cells, i.e. the capability 
of non-toxic action on normal cells while exhibiting 
toxic activity with respect to malignant cells. Further- 
more, these commercial polymers are not well charac- 
5 terized as to structure and molecular weight and are of 
questionable purity. 
Monomeric plyquaternary cations of aliphatic and 
heterocyclic structbre such as ditertiary aliphatic di- 
amines and bisquatemary pyridine compounds have 
Space Act of 1958, Public Law 10 been suggested for use as curariform and anti-tumor 
agents. The binding efficiency, toxicity and duration of 
SUMMARY OF THE INVENTION 
In accordance with the invention, it has now been 
discovered that polycationic ionene polymers and espe- 
cially particular ionene polymers under controlled dos- 
age limits exhibit selectivity toward malignant mamma- 
lian cells when added to a mixture of normal and malig- 
IONENE POLYMERS FOR SELECTIVELY 
INHIBITING THE VITRO GROWTH OF 
MALIGNANT CELLS 
,ORIGIN OF THE INVENTION 
The invention described'herein was made in the per- 
formance of %ork under a NASA contract and is sub- 
ions Of Section 305 Of the National 
83-568 (72 Stat. 435; 42 USC 2457). 
CROSS REFERENCE TO RELATED APPLICATION 
This is a division of application Ser. No. 398,376, 
activity have not been totally satisfactory. 
l5 filed Sept. 18, 1973, now abandoned. 
BACKGROUND OF THE INVENTION 
l .  Field of the Invention 
The present invention relates to biologically active 
polyquaternary pobmers* and more particularly, to the 2o nant cells. In animal tests, the ionene polymers demon- 
strated anti-tumor activity by partial rejection of trans- ers to bind 
planted tumors and increased survival time. In vitro test 
with a mixture of normal and malignant cells demon- 
strated growth of the normal cells while exhibiting toxic 
action toward the malignant cells. The ionene polymers 
are found to be safe and effective under conditions of 
usage* 
These and Other Objects and attendant advantages Of 
3o the invention will become better understood by a refer- 
ence to the following detailed description when consid- 
BRIEF DESCRIPTION OF THE DRAWINGS 
Early work? with cell electrophoresis suggested that 
neopl.astic, proliferating, and embryonal cells have a 25 
higher electro-negative surface charge than other types 
of cells. Each.type of cell exhibits its own characteristic 
electronegativity, Le. lymph node and spleen cells are 
more negative than thymocytes and macrophages. Cell 
membrane acid anions are the major cause of 
surface negative charge. M~~~ recently, a uniformity of 
rted. The malignant cell lines HeLa 
(cervical cancer), HEp2 (laryngeal carcinoma), 256 
(rat sarcoma), normal lymphocytes, and normal and 35 
malignant trophoblastic cells were found to have a adhesion Of Cells to gkss Surfaces and to glass Surfaces 
common cell surface coating of an ionic nature not coated with 393-ionene; 
generally found for other normal cell types tested. FIG. 2 is a series of curves showing the cell adhesion 
Electron microscopic studies have also s h o w  that a E a  On glass surfaces and On ionene-treated glass Sur- 
malignant cells have an increased surface thickness of 40 faces; 
mucopblysa&aride material, containiflg terminal FIG. 3 is a pair of curves showing the toxic effect of 
ern between normal and leukemic ered in conjunction with the accompanying 
is a series Of curves showing the 
ed sialic acid moieties. 3,340nene on a mixture of normal and malignant cells; 
to cure or treat malignant and 
lectrostatic characteristic of FIG. 4 is a pair of curves showing the toxic effect of 
ion molecules may be mo- 45 6,lO-ionene on a mixture of normal and malignant 
w or high molecular weight, 
DESCRIPTlON OF THE PREFERRED may have their charged 
EMBODIMENTS sulfonium, or phospho- or pendant to the chain, with resulting 
biological properties extremely dependent upon these 50 The ionene polymers of interest in this invention are 
parameters. Many water soluble compounds are com- water-soluble, linear polymers, without cross-linking or 
mercially )available. ~. branching. The polymers have a molecular weight from 
A difficulty in attempting to exploit electrostatic 3,000 to 100,OOO, generally from 10,000 to 60,000 and 
phenomenon in therapy of malignant disease stems are solids at room temperature and have an average 
from the lack of specificity for tumor cells by polyca- 55 charge of at least one intra polymeric quaternary nitro- 
tions and also the constantly changing surface chemis- gen for an average of every 12 chain atoms. 
try of cell membranes. Nevertheless, the possibility of 
employing. polycations for preferential growth inhibi- 
tion of malignant cells has been attempted. 
polyethylene imine (PEI), polypropylene imine (PPI), 
polyvinylimidazolinium (PVA), and diethyl amino 
growth of allogeneic and syngeneic tumors in mice at 
non-toxic levels to the host. Anti-tumor activity ap- 65 
pears related to the polycation type, molecular weight, 
zeta potential and route of injection. While these 
agents are cytotoxic, only a few ve been shown to 
cells. 
The i nes have the general structure: 
Several classes of polycations, primarily quaternary 60 
ethyl dextran (DEAD) have been found to inhibit the R' 
where R' and R2 are methyl, R3 and ,R4 are divalent 
aliphatic, aromatic or heterocyclic groups containing at 
least 3 carbon atoms, or R3 combined with R' and R2 
4,013,507 
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forms a cyclic group and Z- is an anion, generally compounds. Dihalo aromatic compounds such as 0, rn, 
chloro, bromo or iodo. and p-dichloro or -dibromo xylene may also be utilized. 
Aliphatic ionene polymers in which R3 and R4 are the A compound of particular utility can be formed from a 
same polymethylene group of the formula (CH,), dihalo compound of known anti-tumor activity. For 
where x is 3 or more than 6 can be prepared by homo- 5 example, cyclophosphamide, commercially known as 
polymerization of tertiary amino alkyl halides of the cytoxan, can be reacted with ditertiary amines to form 
formula ' biologically active polymers in accordance with the 
invention. 
Z(CH,), N(CH& The diamine reactant for the copolymerization reac- 
in accordance with the procedure disclosed in copend- I O  tion may be represented by the formula: 
ing application Ser. No. 280,649, filed Aug. 14, 1972. 
Values of x between 4 and 7 result in cyclic products. 
tion of ditertiary amines and dihalo organic com- 
of linear polymers in which the distance between posi- 
R' R' 
Ionenes can also be prepared by the copolymeriza- I I 
N-RS-N 
R' R* 
I I .  
pounds. This reaction permits the synthesis of a variety I 5 
tive nitrogen centers can be varied at will. With ali- 
phatic ionenes of the formula: where R3 is aliphatic, aromatic, heterocyclic or R3 when combined with R1 and R2 forms a cyclic group. 
Representative compounds'are N,N,N',N'-ietramethyl- 
2o 1,3-diamino propane, N,N,N',N'-tetramethyl- 1,3-hex- 
amethylene diamine (THD) and N,N,N',N'-tetrame- 
thy1 1,lO-decamethylene diamine. Examples of hetero- 
cyclic or aromatic compounds are 1 ,2-bis-( 4-pyridy1)- 
ethane, -propane or -butane, dipyridyl, diazo-bicy- 
25 clooctane or tetramethyl diamino, diphenyl methane. 
the values of and between and 6 must also be The copolymerization synthesis of the invention is par- 
selected to avoid formation of cyclic compounds, as ticularly adaptable to precursors of -known anti-tumor 
(1972), the disclosure of which is incorporated herein mula: 
disclosed by Rembaum et al. Macromolecules 5 261 agents the bis-pyridyl Of the for- 
by reference. and the corresponding 3-phenyl pyridine isomer 
Well defined conditions Of synthesis relating to for- thereof which have h e n  s h o w  to be very effective 
mation of relatively high molecular weight ionenes are 40 against the L 12 10 leukemia system when quatemized 
disclosed by Rembaum et al, J. Polym SCi., Part B 6 159 ( J. Med. Chem. 10, 706, 1967). 
( 1968). the disclosure of which is incorporated herein The invention will now be illustrated by the following 
by reference. Generally, high molecular weight ionene examples. 
polymers are prepared in a 0.1 to 2.5 molar solution of 
a ditertiary amine and a dihalo organic compound in 45 
solvent at temperatures below about 50" C. Higher 
polymerization rates occur in polar organic solvents 
. EXAMPLE1 
Tetramethyl-3.4-Ionene Bromide 
such dimethyl formam& (DMF), dimethyl sulfox- Tetramethy1-3*4-ionene bromide was produced 
ide (DMSO), methanol, preferably a mixture of DMF l d e r  the following conditions: 6.26 8 of N,N,N',N'- 
and methanol. tetramethyl-1.3-diaminopropane and 10.4 g of 1,4- 
of the dibromobutane were dissolved in methanol, total vol- 
fornula ZR4z where is &Ioro, bromo or iodo, where ume 25 ml. The resulting solution was equilibrated at 
R4 is a divalent organic radical such as alkylene, aryl- 25" C for 1 week. Immediately prior to isolating the 
ene, alkarylene or aralkylene. Hydrocarbon R4 groups product, an aliquot was for unquatemized 
may also be intempted with atoms such as nitrogen, 55 amine, which was found to be 0.5% of the initial mono- 
oxygen or sulfur and may be substituted with diverse mer* The =Ivent was flash and the poly- 
zation reaction or activity of the polymer or promote (88% geld) Of 3-4,ionene bromide W a s  isolated. Bro- 
undesirable side effects during use. mine analysis gave 42.6% ionic bromine compared to a 
Representative dihalo organic are a,8 6o theoretical value of 46.2%. The intrinsic viscosity of 
chloro or bromo terminated compounds such as 1.3- the polymer, as determined in 0.4 M KBr (aq). was [ n] 
dichloropropane, 1,3-dibromopropane, 1.4- = 0.194 dl/g corresponding to a molecular weight of 
dichlorobutane, 1,6dibromobutane, 1,4-dichloro-2 about 45,000. 
-butene, 1,4-dibromo-2-butene, 1.4-dibrom0-2.3-dihy- 
droxy butane, 1 ,5-dichloropentane, 1,6-dibromohex- 65 
ane, 1,8-dichlorohexane, 1 , 10-dichlorodecane, and ,440eene Chloride 
1,16-dichlorohexadecane. The alkenylene compounds 
are more reactive than the corresponding saturated 
The dihalo organic material is a 
pendant groups that do  not interfere with the polymeri- mer dried under vacuum at 40" for 24 hours* 16a7 g 
EFAMPLE 2 
The chloride corresponding to the ionene polymer of 
Example 1 was prepared by substituting an equivalent 
4,013,507 
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amount of 1 ,4-dichlorobutane for the dibromobutane 
and following the procedure of Example 1. 
EXAMPLE 3 
6,lO-Ionene Bromide 
N,N,N',N -tetramethylhexamethylene diamine 
(THD), (one equivalent) is mixed with normal di- 
bromodecane (one equivalent), each material having 
been previously dissolved in a 1 : 1 by volume mixture of 
dimethylformamide and methanol. The mixture was 
allowed to react at room temperature for a period of 1 
to 10 days. At the end of this time, benzene was added 
to the mixture. The precipitated solid which formed 
was filtered, washed with benzene, and suitably dried. 
The yield was about 90-99% based on theoretical, of a 
white crystalline solid with a molecular weight of about 
50,000. Spectral and elemental composition analysis 
showed the structure to be a linear polymer of the 
formula: ii'" N+-(CH,).-N+-(CH,),, f 
CH, CHn 
EXAMPLE 4 
6,lO-Ionene Chloride 
The corresponding chloride was formed by substitut- 
ing an equivalent amount of dichlorodecane for the 
dibromodecane and following the procedure of Exam- 
ple 3. 
EXAMPLE 5 
3,3-Ionene Bromide 
A 1 : 1 molar solution of tetramethyl diaminopropane 
(0.2 mol) was thoroughly mixed with 1,3-dibromopro- 
pane (0.2 mol) in 1:l DMF/methanol by volume. The 
mixture was left at room temperature (ca. 22" C) for 9 
days. The polymer was filtered, washed quickly with a 
small amount of solvent, then with benzene and finally 
with acetone and dried under high vacuum at 40" C to 
yield a polymer having a molecular weight of about 
55,000. 
EXAMPLE 6 
3,3-Ionene Chloride 
The corresponding chloride was formed by substitut- 
ing an equivalent amount of dichloropropane for di- 
bromopropane and following the procedure of Exam- 
EXAMPLE 7 
. ple 5. 
PC-6 
Cyclophospamide and an equivalent amount of (ro- 
tetramethyl amino-n-hexane were reacted in bulk at 
SO" C for 48 hours to form a new polymer which was 
named polycytoxan-6( PC-6), having a molecular 
weight of at least 10,000 and having the following 
structure: 
Based on an area of 100 A'* per molecule, the 
l 5  charge density of 3,440nene has been estimated at 9.6 
X electrostatic units/Ao2 and for 6,6-ionene at 
6.4\X esulAo2. 
Due to the high positive charge density and high 
water solubility, ionenes strongly interact with a wide 
2o variety of cell materials. Ionene polymers exhibit toxic 
effects when injected into mice intraperitoneally (i.p.). 
The i.p. lethal dose for 50% survival (i.p. LD5,) is, 
however, comparable to that of a number of clinically 
25 used drugs. Oral administration of ionene polymers is 
considerably less toxic than intraperitoneal. A compar- 
ison of i.p. LDso with oral i.p. LDW is shown in the 
following Table in which the toxicity data for some low 
molecular weight ammonium salts are also included. 
30 TABLE I 
TOXICITY OF POLYMERIC VERSUS 
MONOMERIC COMPOUNDS 
i.p. LD50 
m g k  
35 3.3-ionene bromide 50-100 
2.4-ionene bromide 50-100 
2.6-ionene bromide 50-100 
6.3-ionene bromide 50-100 
6.4-ionene bromide 50-100 
6.5-ionene bromide 50-100 
6,640nene bromide 50-100 
6.16-ionene bromide 50-100 
40 6,10-ionene bromide 10-50 
Oral LD50 
m g k  
500-1000 
>loo0 
> I O 0 0  
>loo0 
>loo0 
>loo0 
>loo0 
500-1000 
>IO00 
55 CH1\+/CH3 
fi 
100-200 >loo0 
> I O 0 0  > I O 0 0  
CHn CHJ 
65 
The ionene polymers of this invention may be utilized 
to cure and treat traumatic conditions of warm blooded 
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animals and particularly mammals such as dogs, cats . biological materials. Since it has been suggested that 
and humans. The polymers will find use in clinical and malignant cells are more electro-negative than normal 
veterinary medicine and as diagnostic agents and as cells, malignant cells should demonstrate a greater 
agents useful in the study of biosynthesis mechanisms affinity for the electro-positive ionene polymer. A se- 
of growth of normal and abnormal cells. The polymers 5 ries of studies were carried out to evaluate the degree 
may be ingested orally or may be administered by sub- of cellular adherence and spreading capacity of normal 
cutaneous, intermuscular or intraperitoneal+ routes. and SV-40 transformed human cells (WI-38) on nor- 
The iOnene Polymers are suitably dispersed or dis- mal glass surfaces and on glass which was coated with 
solved in a PharmacologicallY acceptable Carrier such ionene. In the study, mammalian cells were in culture 
as aqueous Phosphate buffer at a PH Of about 7 Or 10 with ionenes as molecular probes to understand the cell 
more. The Polymers may also be compounded with membrane properties. The surface of most mammalian 
inert adjuvants Or excipients such as flavoring agents, and avian cells has a net negative charge. Several al- 
coloring agents and fillers and extenders to package the tered cell membrane characteristics are most notice- 
ionene polymer in a dosage form. The Polymer able in transformed cells. This results in an impairment 
may be administered on a regular daily basis since it has 15 of the social interactions evolving at cell surfaces, in- 
shown sustained, long-term activity or may be adminis- herent in malignancy. With exceptions, the net 
tered in smaller dosages several times a day on a sched- surface negativity increases by abut 20% in a trans- 
uled basis as indicated by the condition of the subject. formed cell. m i s  difference in the surface charge re- 
animal, the condition being treated and the route of 20 differential cel~-substratum adhesion, since the sub- 
administration. The dosage' level by oial route must be 
Minimum dosage depends On the weight Of the sults in the differential cellcell aggregation and also in 
stratum-like glass also has a net negative charge. 
maintained below about 500-1000 mgkg and below using normal human diploid fibroblast cells WI-38 
50-100 mg/kg by the i.P. route. Animal' experiments and its SV-40 transformed derivative WI-38 VAl32RA 
mdkg and preferably 5-25 mg/kg administered intra- 25 ducted with 3,3-ionene bromide and 6, IO-ionene bra- 
have indicated that a daily dosage level of at least 1 
peritoneally is safe and effective in the treatment of 
animals with malignant tumors. Daily' oral dosages of 
50 to 2oo mdkg would appear to be safe and 
effective. 
other pharmacologically active compounds of similar 
or complementary activity. Ionene polymer therapy 
may be combined with other polycations such as poly- 
ethylene imine or with heparin. 
rin. The solubility of these complexes 
structure of ionene and the molecular 
son for the antiheparin activity of ionenes. 
(sv-40-wI-38), a series of experiments were con- 
mide on the cell adhesion, and cell spreading on glass 
surfaces coated with ionenes. Preliminary studies on 
differential toxicity to normal and transformed cells 
were also conducted. 
The polycation-coated glass surface would shift the 
surface charge in favor of positivity, accelerating the 
cellular adhesion. Since the transformed cells have 
about 20% more negative charge than the normal an- 
faster than the normal cells to polycation-coated glass 
surfaces. WI-38 cells of passage 17-22 and SV-40-WI- 
periments. 
Ionene polymers may be utilized in combination with 30 
Ionenes form water insoluble compl&es with hepa- 35 the transformed may adhere and spread 
on the 
ts of both 
components. Complex fornation is probably the rea- 38 Of passage 194-206 were utilized in these ex- 
protamine sulfate and toluidine blue, neither of 4o Adhesion of cells was routinely measured in multi- 
antiheparin agents. Although most ionene structures glasses were used as substratum for cell adhesion. Two 
have &heparin activity, extensive investigations of of the coverglasses were soaked for 30 minutes in 3,3- 
toxicology and effects on the circulatory' system in ionene Br solution (2Pdml) in Ca++ and Mg++ free 
laboratory animals were carried out with 6,3-ionene 45 Hanks solution, rinsed twice with Ca++ and Mg++ free 
bromide. The latter was found to be more toxic (the i.v. Hanks solution (PH 717 the other two served as 
LD, being 28 mdkg in mice and 20 mg/kg in rats; the controk+ 
i.p. LD, in mice being 61.5 mg/kg) than toluidine blue Three 4 day old cultures were wed. Cells were trYP- 
(i.v. LD, 45 mg/kg) and protamine sulfate (i.v. LD, sinised with 0.25% trypsin; rinsed three times in serum 
44 mdkg). However, cumulative i.v. doses of 6,3- 50 free Eagle's medium. 4 ml aliquots of 5 x 105 Cells in 
ionene bromide up to 5 mdkg as 1% solutions could be serum free medium (PH 7.2-7.4) were inoculated in 
given rapidly to anesthetize dogs without markedly each chamber and incubated at 34" c. At different 
affecting either the respiration or circulation, i.e., with- intervals, the multiplates were subjected to gyratory 
out toxic symptoms. shaking for 3 minutes in a shaker at 220 rpm; the 
Heparin offers a protective action in neutralizing the 55 weakly attached and floating cells were drained; the 
toxicity of 6,3-ionene bromide in both mice and dogs. coverslips were rinsed in saline and fixed in 2% glutar- 
Thus pretreatment of mice with heparin enabled them aldehyde in saline. 
to survive doses three times the LD, values with only The coverslips were examined in the microscope and 
mild toxicity symptoms. This is not surprising consider- cells were counted in 8 different randomly selected 
ing the formation of relatively stable complexes be- 60 areas and the mean number of cells per unit were cal- 
tween ionenes and heparin. culated. The number of cells adhered as a function of 
The nature of binding of ionene polymers and the time is shown in FIG. 1. 
resultant biological activity against normal and cancer- The data indicates that the number of cells attached 
ous cells was tested by in vitro growth experiments. The to 3,3-ionene treated coverglass is greater than that of 
host cells were normal eipthelial human lung cells (WI- 65 untreated coverglass. This would probably mean that 
38) and SV-40 transformed WI-38 cells. Due to the more adhesive sites are established in the presence of 
high positive charge density and high water solubility, the polycation coating increasing the strength of adhe- 
the ionenes strongly interact with a wide variety of sion within the given time. 
which are free of toxic effects, are clinically used as plate (Lux Scient- Corp.1 in which Gold seal cover- 
8 
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Cell flattening or cell spreading was also accelerated 
in both normal and transformed WI-38 cells. This was 
studied by randomly selected photographs (uniform 
magnification) of cell samples, carefully marking the 
cell boundaries and cutting the photographs along the 5 waterinsoluble complexes with DNA. 
boundary and weighing a total of 3 0 4 0  cells/treatment 
at different times. .The area of a cell on the glass is 
shown in arbitrary units in the following table and plot- 
ted in FIG. 2 as a function of time. This data has the 
limitations of light microscope resolution. 
Table 2 
Area occupied by a cell on the glass surface in arbitrary 
on an ionene-coated surface and indicated the involve- 
ment of sulfhydryl groups on the cell periphery in the 
process of cell adhesion. Chemical interaction with 
DNA is also a possibility. In fact, ionenes form strong 
An aqueous solution of calf thymus DNA (Ma con- 
tent of 5.9%) when mixed with an aqueous solution of 
6,lO-ionene bromide (Br content 33.9%) results in a 
solid fibrous precipitate which when dry contains only 
10 0.03% of Na and 0.2% of Br. The complex can be 
obtained in the form of fibers exhibiting strong birefrin- 
gence in a polarizing microscope, and this implies that 
the helical configuration of DNA was preserved. The 
elemental analysis results indicate electrostatic bond- 
10 min. 20 min. 40 min. 60 min. 15 ing between the negative oxygen of the DNA phos- 
phate groups and the positive nitrogens of the ionene 
untreated glass 1.0 1.3 1.6 2.0 and elimination of sodium bromide during complex 
WI-38 cells on ' formation. Although different structures of ionenes 
yield similar complexes, an examination of DNA mo- 
on untreatedglass 1.0 1.1 1.3 1 .4  20 lecular models shows that the 6,10-ionene gives the 
SV-40-W1-38 cells on best fit if we assume that the latter wraps itself around 
3.3-ionene surface 1.0 2.0 3.5 3.5 the DNA double helix. 
I 
units. (Each number is an average of 3 0 4 0  cells) 
Wl-38 cells on 
3.3-ionene surface 1.3 1.7 2.3 2.1 
SV-40-WI-38 cells 
The ionene-DNA complex is soluble in high inonic 
strength solutions (0.5 M NaCI) but its stability has not 
25 yet been determined. Similar complexes have been 
obtained with polyamines of the following structures: 
There is an acceleration in cell spreading in both 
normal and transformed WI-38 cells in the presence of 
3,3-ionene coating, which is markedly pronounced in - _  
the SV-40 transformed WI-38 cells. NHz(CH2)3-NH-( CHz),NH, 
Spermidine 
NH2( CH2 )&H( CH2 )4NH( CH2 )sNH2 
Spermine 
This is compatible with the assumption that polyca- 
tion coated glass surfaces have more positive charges 3o 
and the high negativity of the transformed cell mem- 
brane. One experiment was conducted with SV-40 
transformed 3TC cells (Balb c mouse). These also 
arked increase in cell spreading on the 
Putrescine polyionene treated glass surface. 
Differential toxicity studies were conducted by Cod- mese po~yamines, in spite of the fact that they exhibit 
ter counter analysis of WI-38 and SV-40 transformed high toxicity when injected in vivo, are present in most 
cells in suspension in Eagle's medium treated with vari- living organisms and affect a large number of metabolic 
ous concentrations of 3,3-ionene Br and 6, IO-ionene transformations. spermine was discovered in the 
Br and incubated for three days at room temperature. 40 human Semen as long ago as 1678 by Leeuwenhoek. It 
3,3-ionene showed only moderate differences in the is known that spermidine and spermine and the 
growth and rates Of the two as related diamine, putrescine, are ubiquitous in animals 
in FIG. 3. 6,10-ionene bromide showed highly specific and and at least one of these three mines is 
toxicity to cancer cells, while the normal c e k  showed present in all micro-organisms. Spermidine and sper- 
a slight stimulatory response with UP to 4 Pdml con- 45 mine bind to DNA and may be attached like the his- 
centration of 6,lO-ionene Br as shown in FIG. 4. The tones along sections of a DNA molecule. Polyamines 
exact mechanism Of specific toxicity to transformed also have a marked stimulatory effect on the enzyme 
cells is not known. It is probable that electrokinetic synthesizing ribonucleic acid (RNA) that is DNA 
binding of the ionene to the negatively charged surface primed RNA polymerase. They also stimulate the DNA 
causes charge neUtraliZatiOn and Cytotoxic reaction. 50 replicating enzyme (DNA -primed DNA polymerase) 
The toxic activity may also result from pinocytosis by and may stabilize the low molecular weight RNA 
polycations binding to the cell nuclei. (transfer RNA). The polyamines interact also with 
It appears that the -lower charge distribution and ribosomes, the subcellular particles which are func- 
pattern of repeating intramolecular charge centers in tional in protein synthesis. 
the 6,lO-ionene polymer backbone is surprisingly mbre 55 Since at  pH 7 the polyamines exist in the form of 
toxic to cells than the higher charge distribution in Flycations, their binding to DNA probably involves 
3,3-ionene polymer. These studies have shown that cell the same mechanism as proposed for ionene-DNA 
adhesion and spreading on glass surface is accelerated complexes. The 3,4-ionene can therefore be consid- 
by the presence of polycation coating and shows a ered as a model for polyspermidine or polyspermine 
differential interaction with the transformed cells due 60 and since the molecular weight of ionenes and the 
to higher electronegativity. The charge distribution in number of positively charged nitrogens can be made 
the ionene poljlmer chain may provide higher specific- considerably higher than in naturally occumng poly- 
ity for malignant cells. The different degrees of ionene amines, the number of electrostatic bonds between 
binding of the cells to surfaces also indicates a differen- DNA and ionenes is necessarily higher, therefore the 
tial toxicity toward normal and malignant cells. 65 resulting complexes should be more stable. It must be, 
Though the mechanism of ionene cell interaction is however, borne in mind that the 3,4-ionene, in contrast 
not completely understood, pretreatment of the cells to Spermine, does not contain hydrogen atoms capable 
with N-ethylmaleimide (NEM) inhibited cell adhesion of hydrogen bonding with oxygens of the phosphate 
N Hs - (CH s)4 - N H E 
35 
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groups and this fact may affect the stability of its com- 
plexes with nucleic acids or its biological activity. 
In vivo experiments were conducted by inoculating 
Type carcinoma C3H mice cells. with When 7 the X 105 mice of Type wer  C3H/BA in terminal deno- con 5 
{ ~ ~ - R ~ - ~ ~ - R ~ +  dition, groups of four mice were injected daily by i.p. 
with a daily dose of ionene in phosphate buffer at pH 7. 
Ten control animals received no treatment. The results 
are summarized in the following table. 
Table 4 
where R1 and R2 are lower alkyl, R3 and R4 are divalent 
aliphatic, aromatic or heterocyclic groups containing at 
least 3 carbon atoms, or R3 combined with R' and R2 
forms a cyclic group, Z-  is an anion and n is  an integer; Daily Ionene Dose Percent 
Ionene Number for 30 days of Mice That 
None 10 - 
Rejected Tumor and 
binding said polymer to said malignant cells. 
2. A method according to claim 1 in which the cells 
3,4-Bromide 4 12.5 25 ' 5  are mammalian cells. 
6,lO-Bromide 4 7.5 25 3. A method according to claim 2 in which the con- 
centration of ionene polymer is no greater than 4 
AS Can be Seen, One Of each animal in the treated 4. A method according to'claim 2 in which the ionene 
group rejected the transplant. Two of the four mice 20  polymers have a molecular weight from 10,~)oo to 
administered 3,440nene bromide survived the last con- 
trOl by ten days. All the control animals developed 5. A method according to claim 4 in which R3 and R4 
tumors and died within 38 days. Of the ionenes tested, 
the 6, IO-ionene bromide exhibited the strongest toxic- 
ity toward tumor cells. One C U E  WaS achieved when 25 
3,3-ionene bromide was combined with a polyethylene- 
imine and injected into a mouse with transplanted 
tumor in terminal condition. 
T W O  C3H type mice in terminal condition with ade- 
nocarcinoma from transplanted tumors (seven weeks 30 
old) were injected twice within 4 hours intrapentone- 
ally with 500 Pg Of pc-6 (Example 7). A dramatic 
improvement waS observed. Within one day the general 
health condition of the mice improved visibly and the 
diarrhea was stopped. The behavior of the mice contin- 35 applied. 
ued normal for eleven days after injection. In another 
test, two B 16 type mice with melanoma were similarly 
treated with equally encouraging results. 
pc-6 differs from cYcbJhosPhamide, a well-known 
clinically used antileukemia and antitumor drug, in its 4o 
biological activity, toxicity and other properties. Nine 
doses of PC-6 of 100 mg/kg per day each were injected 
into 12 mice without visible ill effects as observed dur- 
ing this time. Similar doses of cyclophosphamide are 
lethal within a much shorter time. 
Though the ionenes have been discussed and tested 
in their halide form, they may be converted to other 
anion forms for use. The ionene binding of electronega- 
tive cells will find use in clinical and diagnostic medi- 
cine. A diagnostic test for cancer can be practiced by 
culturing a tissue sample with 6,lO-ionene bromide at a 50 
concentration of between 2-4 pg/ml and determining 
the presence of any dead cells in the culture since 
under these conditions normal cell growth is promoted 
while the ionene is toxic to malignant cells. 
ments of the invention have been described and that 
numerous substitutions, alterations and modifications 
may be made without departing from the spirit and 
scope of the invention as defined in the following 
claims. 6 0  4pg/ml. 
Polymer of Mice mgk? 
0 
3.3-Bromide 4 12.5 25 
Pg/ml. 
60,000. 
are selected from alkylene, alkenylene, arylene, alkary- 
lene and aralkylene. 
6. A method according to claim 5 in which R3 and R4 
are alkylene of 3-16 carbon atoms and R1 and R2 are 
methyl. 
7. A method according to claim 6 in which R3 is 
hexamethylene and R4 is decamethylene. 
8. A method according to claim 1 further including 
the step of coating the ionene polymer onto a surface 
9. A method according to claim 8 in which the sur- 
face has a net negative charge before said coating is 
10. A method of determining the presence of malig- 
culturing said cells; 
adding to said culture ionene polymer in an amount 
sufficient not to inhibit growth of normal cells and 
in an amount toxic to said malignant cells; said 
ionene polymer having a molecular weight from 
3,000 to 100,000 of the formula: 
and applying the cell mixture to the coated surface. 
nant cells in a cell mixture comprising the steps of: 
45 
N+-Rn-N+-R* {;- ;:- 1 
where R1 and R2 are lower alkyl, R3 and RS are divalent 
aliphatic, aromatic or heterocyclic groups containing at 
least 3 carbon atoms, or R3 combined with R1 and R2 
forms a cyclic group, Z- is an anion and n is an integer; ' 
determining the presence of dead malignant cells in 
11. A method according to claim 10 in which the 
ionene is a 6,10-ionene and the concentration is below 
12. A method according to claim 10 in which said 
cells are cultured on a surface having a net negative 
charge and further including the step of coating said 
surface with said ionene polymer. 
13. A method according to claim 12 in which the 
surface is glass. 
14. A method according to claim 13 in which a s o b  
tion of ionene polymer is applied to the surface. 
It is to be understood that only preferred embodi- 55 and 
the mixture. 
What is claimed is: 
1. A method of selectively inhibiting the in vitro 
growth of malignant animal cells comprising the steps 
Of: 
adding to a mixture of normal and malignant cells an 65 
ionene polymer in an amount sufficient to selec- 
tively inhibit the growth of said malignant cells, 
said polymer having a molecular weight from 3,000 
to 100,000 of the formula: * * * * *  
